Affymax, Inc.
Affymax, Inc., officials report on new developments
Published in Medicine and Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Affymax, Inc.
Report 1: Affymax, Inc. (Nasdaq:AFFY) announced that it plans to initiate Phase 3 clinical studies with Hematide(TM) in chronic renal failure patients following recent discussions with the United States Food and Drug Administration (FDA) on the design of the Phase 3 clinical trial program. Hematide is the company's lead drug in development for the treatment of anemia.
"Following meetings with the FDA, we believe we are well positioned to take advantage of the most...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Addiction Medicine
Findings from University of Connecticut, Health Center broaden understanding of addiction medicine - Bioengineering
Research reports on bioengineering from University of Aveiro provide new insights - Bioethics
Researchers' work from National Tokyo Medical Center, Division of Clinical Epidemiology focuses on bioethics - Biomedicine
Scientists at University of Illinois report research in biomedicine - Biomedicine
Scientists at University of Sydney discuss research in biomedicine - Cardiology
Findings from University of Michigan, Department of Internal Medicine in cardiology reported - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
